- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00780299
Hemodynamic Efficiency of an Hemodialysis Treatment With High Permeability in Post-resuscitation Shock (Hyperdia)
Hemodynamic Efficiency of an Hemodialysis Treatment With High Permeability (HDHP) During the Early Period of Post-resuscitation Shock
Rationale: Despite spontaneous cardiac activity recovery, a shock occurs in more than half of patients after resuscitation for cardiac arrest. This acute circulatory insufficiency presents similar characteristics with septic shock and is responsible of most early deaths. Most frequently, usual treatments are unable to control this shock and to avoid the appearance of multiple organ failure.
Aim of the study: In addition to conventional therapeutics, an early plasma epuration of inflammatory mediators (HDHP) could be able to improve hemodynamic parameters and to reduce the shock duration. This improvement could have an impact on multiple organ dysfunctions and also on early mortality.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HDHP (plasma epuration of inflammatory mediators) will be used in addition to the current clinical practice. The experimental arm will be treated by HDHP device.
The high permeability membrane SepteX is a membrane polyarylethersulfone sold by Gambro that allows the purification of molecules of average size to near 50 kd molecular weight.
We can thus purify molecules larger molecular weight than hemofiltration can with the usual membranes (30 kd). Furthermore, this increase in permeability allows a significant treatment medium-sized molecules in diffusion (hemodialysis), that the usual membranes do not allow. Finally, it is possible to purify certain molecules that hemofiltration including high volume does not allow (TNFalpha for example).
Use of this membrane requires the use of specific set dedicated machine Prismaflex itself with a specific software (Exceed) to ensure the control and security of processing.
2 sessions of HDHP will be performed in the first 48 hours following ICU admission (with inclusion in the first 8 hours).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75679
- Medical intensive care unit of Cochin-St Vincent de Paul university Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Comatous patients admitted to the ICU for a sudden cardiac death apparently related to heart disease and requiring catecholamine infusion to treat a shock
- Cardiac arrest in front of witnesses
- Written informed consent obtained from the family or by emergency procedure
Exclusion criteria
- Age under 18 years
- Response to verbal commands (Glasgow score >7)
- Terminal illness present before the cardiac arrest
- Acquired or innate immune deficit
- Anticoagulation not recommended or high hemorrhagic risk
- pregnancy
- weight > 100 kg
- without social security
- another clinical trial ongoing
- cardiac arrest from non cardiac etiology
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 2
control
|
hemofiltration intermittent dialysis
|
Experimental: 1
HDHP
|
HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The main endpoint will be the duration of the shock expressed by the length of catecholamine infusion
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in organ dysfunction score (SOFA, LOD) during the first 7 days Mortality at day 7 and day 28 Incidence of side effects and complications due to HDHP Impact of HDHP on inflammatory parameters.
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Alain Cariou, MD, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P071005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shock
-
Assistance Publique - Hôpitaux de ParisTraumabase Group; Capgemini Invent; Ecole polytechnique; EHESS (Ecole des hautes... and other collaboratorsRecruitingWounds and Injuries | Hemorrhagic Shock | Traumatic ShockFrance
-
Biomedizinische Forschungs gmbHMedical University of ViennaCompletedSepsis | Toxic-Shock Syndrome
-
King's College Hospital NHS TrustUniversity Hospital BirminghamCompletedTraumatic Haemorrhagic ShockUnited Kingdom
-
Haukeland University HospitalMinistry of Defence, NorwayCompletedHemorrhagic Shock | Hypovolemic ShockNorway
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Boston Medical Center; Tufts Medical Center and other collaboratorsRecruiting
-
Jason SperryNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHemorrhagic ShockUnited States
-
University of Texas Southwestern Medical CenterUniversity of Washington; Resuscitation Outcomes ConsortiumCompletedHemorrhagic ShockUnited States
-
Ramathibodi HospitalUnknownSeptic Shock | Refractory ShockThailand
-
National Institute of Allergy and Infectious Diseases...Completed
-
Assiut UniversityUnknown
Clinical Trials on CVVH
-
Children's Hospital of Fudan UniversityShandong Provincial Hospital; First Affiliated Hospital of Xinjiang Medical... and other collaboratorsNot yet recruiting
-
Ruijin HospitalRenJi HospitalUnknown
-
CytoSorbents, IncSan Antonio Military Medical Center (SAMMC), US Army Institute of Surgical...WithdrawnRhabdomyolysisUnited States
-
Hospices Civils de LyonBaxter Healthcare CorporationCompletedSeptic Shock | PeritonitisFrance
-
Peking Union Medical College HospitalUnknownCOVID-19 | ECMOChina
-
Baxter Healthcare CorporationGambro Dialysatoren GmbHCompleted
-
Onze Lieve Vrouwe GasthuisCompletedAcute Renal Failure | Multiple Organ Failure | KidneyNetherlands
-
Medical University InnsbruckCompletedAcute Kidney Injury | Critically Ill | Renal Replacement Therapy | Continuous Renal Replacement Therapy | Continuous Veno-Venous Hemofiltration | Replacement Fluid | Phoxilium | Biphozyl | Anticoagulation | Regional Citrate AnticoagulationAustria
-
University of ChicagoNxStage MedicalCompletedAcute Renal FailureUnited States